SFZNZ Stock Overview
Provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 974.00 |
| 52 Week High | CHF 1,190.00 |
| 52 Week Low | CHF 827.00 |
| Beta | 0.70 |
| 1 Month Change | -11.93% |
| 3 Month Change | -14.71% |
| 1 Year Change | 15.88% |
| 3 Year Change | 10.74% |
| 5 Year Change | n/a |
| Change since IPO | 652.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| SFZNZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -7.6% | -8.8% | -2.6% |
| 1Y | 15.9% | -29.8% | 2.7% |
Return vs Industry: SFZNZ exceeded the UK Life Sciences industry which returned -27% over the past year.
Return vs Market: SFZNZ exceeded the UK Market which returned 3.5% over the past year.
Price Volatility
| SFZNZ volatility | |
|---|---|
| SFZNZ Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SFZNZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SFZNZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,797 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide. It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services. The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
Siegfried Holding AG Fundamentals Summary
| SFZNZ fundamental statistics | |
|---|---|
| Market cap | CHF 4.18b |
| Earnings (TTM) | CHF 128.86m |
| Revenue (TTM) | CHF 1.28b |
32.4x
P/E Ratio3.3x
P/S RatioIs SFZNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 1.28b |
| Cost of Revenue | CHF 952.10m |
| Gross Profit | CHF 332.25m |
| Other Expenses | CHF 203.38m |
| Earnings | CHF 128.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | 30.04 |
| Gross Margin | 25.87% |
| Net Profit Margin | 10.03% |
| Debt/Equity Ratio | 47.4% |
How did SFZNZ perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 01:24 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Siegfried Holding AG is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Lopez Pineda | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |